Bristol Myers Squibb (NYSE: BMY) announced that Opdivo® (nivolumab) has received approval for two new classical Hodgkin Lymphoma (cHL) indications in the U.S. and the European Union. (Joplin Globe)
In the U.S., FDA approval establishes Opdivo in combination with doxorubicin, vinblastine and dacarbazine (AVD) as the first immunotherapy combination approved for adult and pediatricpatients aged 12 and older with previously untreated, Stage III or IV cHL. In the EU, Opdivo in combination with brentuximab vedotin is now the first immunotherapy combination approved to treat certain pediatric and adult patients with relapsed or refractory cHL. (Bristol Myers Squibb)
The U.S. approval is based on the Phase 3 SWOG 1826 study, which demonstrated improved progression-free survival compared to the standard of care regimen BV-AVD. (Morningstar)
Classical Hodgkin Lymphoma is the most common cancer diagnosed in adolescents aged 15–19 and accounts for 95% of all Hodgkin Lymphoma cases. (WBOC)
Written by- Sayan Das
Graphics By: Pramit Hazra
